



December 27, 2016

Abiomed to Present at the 35th Annual J.P. Morgan Healthcare Conference

DANVERS, Mass., Dec. 27, 2016 (GLOBE NEWSWIRE) -- [Abiomed, Inc.](http://www.abiomed.com) (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 9:30 a.m. PST / 12:30 p.m. EST. The conference will be held at the Westin St. Francis Hotel in San Francisco, California.

In advance of this presentation, the Company plans to pre-announce preliminary unaudited third quarter fiscal 2017 revenue and U.S. patient utilization growth via press release on Monday, January 9, 2017 at 1:00 p.m. PST / 4:00 p.m. EST.

A live webcast of the Company's presentation at the conference will be available via <http://jpmorgan.metameetings.com/confbook/healthcare17/directlink?p=22722> as well as on the investor section of the company's website at www.abiomed.com. A replay of the webcast will be available for 90 days after the presentation.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

For further information please contact:

Ingrid Goldberg
Director, Investor Relations
978-646-1590
igoldberg@abiomed.com

Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com